|
| related topics |
| {product, candidate, development} |
| {product, market, service} |
| {property, intellectual, protect} |
| {financial, litigation, operation} |
| {product, liability, claim} |
| {system, service, information} |
| {condition, economic, financial} |
| {regulation, change, law} |
| {customer, product, revenue} |
|
|
Certain of the Company s major products are going to lose patent protection in the near future and, when that occurs, the Company expects a significant decline in sales of those products.
The Company s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that have lost patent protection.
Issues concerning Vytorin and the ENHANCE and SEAS clinical trials have had an adverse effect on sales of Vytorin and Zetia in the U.S.
The Company s products, including products in development, can not be marketed unless the Company obtains and maintains regulatory approval.
The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business would be adversely affected.
The Company faces intense competition from lower-cost generic products.
The Company faces intense competition from new products.
The Company faces pricing pressure with respect to its products.
The Company is experiencing difficulties and delays in the manufacturing of certain of its products.
Pharmaceutical products can develop unexpected safety or efficacy concerns.
The Company has no product liability insurance for products first sold after August 1, 2004.
Changes in laws and regulations could adversely affect the Company s business.
The recent financial crisis and current uncertainty in global economic conditions could negatively affect the Company s operating results.
Reliance on third party relationships and outsourcing arrangements could adversely affect the Company s business.
The Company is increasingly dependent on sophisticated information technology and infrastructure.
Cautionary Factors that May Affect Future Results
Full 10-K form ▸
|
|
| related documents |
| 64978--2/28/2008--MERCK_&_CO_INC |
| 310158--2/28/2007--SCHERING_PLOUGH_CORP |
| 310158--2/28/2006--SCHERING_PLOUGH_CORP |
| 891417--3/2/2006--NANO_PROPRIETARY__INC |
| 891417--3/9/2007--NANO_PROPRIETARY__INC |
| 897075--3/17/2008--REPROS_THERAPEUTICS_INC. |
| 64978--2/28/2007--MERCK_&_CO_INC |
| 23259--3/7/2007--CT_COMMUNICATIONS_INC_/NC |
| 38074--6/14/2006--FOREST_LABORATORIES_INC |
| 816284--2/17/2009--CELGENE_CORP_/DE/ |
| 849636--3/16/2006--CORTEX_PHARMACEUTICALS_INC/DE/ |
| 926763--3/16/2007--ASV_INC_/MN/ |
| 880432--9/26/2008--MISONIX_INC |
| 38074--5/30/2008--FOREST_LABORATORIES_INC |
| 38074--5/30/2007--FOREST_LABORATORIES_INC |
| 943736--3/31/2006--MED-DESIGN_CORP |
| 880432--9/28/2010--MISONIX_INC |
| 1208208--2/24/2010--DIGITALGLOBE_INC |
| 351012--8/11/2006--INTERMAGNETICS_GENERAL_CORP |
| 14272--2/22/2008--BRISTOL_MYERS_SQUIBB_CO |
| 14272--2/20/2009--BRISTOL_MYERS_SQUIBB_CO |
| 897075--3/16/2009--REPROS_THERAPEUTICS_INC. |
| 1000694--3/6/2006--NOVAVAX_INC |
| 926763--3/16/2006--ASV_INC_/MN/ |
| 1062822--3/12/2007--LEXICON_GENETICS_INC/TX |
| 926617--4/2/2007--CIPHERGEN_BIOSYSTEMS_INC |
| 881890--6/14/2010--ABAXIS_INC |
| 1009356--3/15/2007--SALIX_PHARMACEUTICALS_LTD |
| 1009356--3/16/2006--SALIX_PHARMACEUTICALS_LTD |
| 1041859--4/12/2006--CHILDRENS_PLACE_RETAIL_STORES_INC |
|